FHD-609 SELECTIVELY DEGRADES BRD9 IN SYNOVIAL SARCOMA GLOBAL PROTEOMICS ANALYSES | BRD9 Is the Only Protein Significantly Degraded at Multiple Concentrations and Time Points - log10 (p-value) - log10 (p-value) - log10 (p-value) negative FC positive FC not significant 16nM (200x DC50) 78nM (1000x DC50) 4hrs in SYO1 16nM (200x DC50) 24hrs in SYO1 4hrs in SYO1 FHD-609 16nM 4h FHD-609 78nM 4h FHD-609 16nM 24h Enhanced Volcano Enhanced Volcano Enhanced Volcano Total = 7,437 Total = 7,437 Total = 7,437 log2 FC lo ...

Item 10. Directors, Executive Officers and Corporate Governance 103 Item 11. Executive Compensation 103 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 103 Item 13. Certain Relationships and Related Transactions, and Director Independence 103 Item 14. Principal Accountant Fees and Services 103 ITEM 1. BUSINESS 6 Table of Contents 3 Foghorn's science and potential have been validated by strategic collaborations with two world-leading pharmaceutical comp ...

FOGHO CORPORATE OVERVIEW Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond November 2022 Forward-Looking Statements FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "could," "may," "might," "will," "l ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________ FORM 10-Q _____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39634 ___________________ ...

FOGHO CORPORATE OVERVIEW Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond September 2022 Forward-Looking Statements FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "could," "may," "might," "will," " ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________ FORM 10-Q _____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39634 ______________________ F ...

FOGHO CORPORATE OVERVIEW Leveraging unique insights into the chromatin regulatory system to pioneer a new class of precision therapies in oncology and beyond June 2022 Forward-Looking Statements FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "could," "may," "might," "will," "likel ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________ FORM 10-Q _____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-39634 ______________________ ...

Overview - The dysregulation of the Chromatin Regulatory System is implicated in approximately 50% of all cancers, representing a significant market opportunity[3] - Foghorn Therapeutics is well-positioned to discover and develop first-in-class precision medicines targeting cancer and other diseases[4] - Foghorn Therapeutics had $479.5 million in pro forma cash and equivalents as of September 30, 2021[5] Pipeline and Programs - FHD-286 (BRG1/BRM) is an enzyme inhibitor targeting AML and Uveal melanoma, with initial clinical data expected in H1 2022[8, 23] - FHD-609 (BRD9) is a protein degrader targeting Synovial Sarcoma, with initial clinical data expected as early as H1 2022[8, 23] - Selective BRM modulators, including enzyme inhibitors and protein degraders, are being developed for BRG1 mutated cancers, impacting over 100,000 patients per year[52] - Selective ARID1B protein degrader is in pre-clinical development for ARID1A mutated cancers, potentially impacting over 175,000 patients per year[60] Strategic Collaborations - Strategic collaboration with Loxo Oncology at Lilly includes $380 million upfront ($300 million cash and $80 million in Foghorn common stock at $20 per share), 50/50 U S economics on two programs, tiered ex-U S royalties, and $1.3 billion in potential milestones[10] - Merck collaboration to drug single specified transcription factor target includes $425 million in up-front, research, development and sales-based milestones and up to low double-digit royalties on product sales[68]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-K _________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39634 _________________________ Foghorn Therapeutics Inc. (Exa ...